US pharma concerns on IP rights and compulsory licensing in India

28 February 2018
drugs_pills_tablets_big

Continuing its tirade against some developed and developing countries, the US drugmakers lobby group Pharmaceutical Research and Manufacturers of America (PhRMA) has urged the office of the US Trade Representative (USTR) to take immediate action to address serious market access and intellectual property (IP) barriers in 19 overseas markets, including India, reports The Pharma Letter’s India correspondent.

In its 2018 Special 301 submission, the organization has called on the USTR to designate Canada, Korea and Malaysia as 'Priority Foreign Countries' and to include Japan, India, and 10 other countries on the 'Priority Watch List'.

Being on the 'Priority Watch List' means that India continues to figure among countries that the USTR feels have 'serious intellectual property rights deficiencies' and do not give adequate protection to US corporate majors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics